thrombophilia

Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report

Coronavirus disease 2019 (COVID-19) is characterized by
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) needing mechanical ventilation and intensive care
unit (ICU) treatment. In addition to lung disease, clinical
features of SARS-CoV-2 include myocardial damage and
ischemia-related vascular disease, which are associated
with a hypercoagulable state (e.g., high D-dimer levels)

Correction: Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia

This article was originally published under an incorrect license. This has now been amended and is available under a CC BY-NC-ND 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma